Samarium-153 therapy for prostate cancer: the evaluation of urine activity, staff exposure and dose rate from patients.

Abstract

The aim of this study was to determine the excretion of Samarium-153-ethylenediaminetetramethylphosphonic acid ((153)Sm-EDTMP) in urine and to calculate the dose rate of its retention in the body as a function of time and the dose received by the skin of laboratory staff's finger. Urine samples were collected from 11 patients after intravenous injection of (153)Sm-EDTMP. The measurements of dose rate were performed. Thermoluminescent dosemeters were used for absorbed dose measurements. Effective half-lives that were calculated from urine sample measurements were found as 7.1±3 h within the first 24 h. Whole body dose rates before collecting urine of patients were 60.0 ± 15.7 µSv h(-1) for within 1 h following (153)Sm-EDTMP administration. The highest finger radiation dose is to the right-hand thumb (3.8 ± 2 mGy). The results of the study imply that patients who recieved (153)Sm-EDTMP therapy should be kept a minumum of 8 h in an isolated room at hospital and that one staff should give therapy at most two patients per week.

• Authors: Yasemin Parlak, Gul Gumuser, Elvan Sayit
• Journal: Radiation protection dosimetry (Radiat Prot Dosimetry) Vol. 163 Issue 4 Pg. 468-72 (Mar 2015) ISSN: 1742-3406 [Electronic] England
• PMID: 25063786 (Publication Type: Journal Article)
• Copyright: © The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: [email protected].

Chemical References

• Analgesics, Non-Narcotic
• Organometallic Compounds
• Organophosphorus Compounds
• Radiopharmaceuticals
• samarium Sm-153 lexidronam

Topics

• Aged
• Analgesics, Non-Narcotic (pharmacokinetics, therapeutic use, urine)
• Bone Neoplasms (metabolism, radiotherapy, secondary)
• Humans
• Male
• Metabolic Clearance Rate
• Middle Aged
• Occupational Exposure (analysis)
• Organometallic Compounds (pharmacokinetics, therapeutic use, urine)
• Organophosphorus Compounds (pharmacokinetics, therapeutic use, urine)
• Prostatic Neoplasms (metabolism, pathology, radiotherapy)
• Radiation Dosage
• Radiopharmaceuticals (pharmacokinetics, therapeutic use, urine)
• Skin (radiation effects)
• Tissue Distribution